Purpose: Increasing use of tramadol for chronic non-cancer pain is concerning since tramadol users may be at risk of developing recurrent opioid use with increasing opioid consumption and co-medication. Therefore, we investigated a complete national cohort of tramadol users. 
| INTRODUCTION
In 1977, tramadol was introduced as a "safe" painkiller with low risk of addiction. 1 Lack of evidence regarding long-term effectiveness and adverse effects including tramadol's abuse potential was disregarded. 2 Tramadol was approved by the US Food and Drug Administration as the only nonscheduled opioid available in 1995. 3 Since recent research has shown that tramadol has a more pronounced potential for abuse and drug overdose than formerly anticipated, [3] [4] [5] [6] tramadol has been rescheduled to a controlled substance in several countries. 4, 5, 7, 8 In Scandinavia, tramadol is among the most commonly used opioid for chronic non-cancer pain (CNCP). 9 During last decade,
Norway and Denmark have experienced an increase in tramadol use
while the consumption has decreased in Sweden and Iceland and has been stable in Finland. 9 The 1-year periodic prevalence of tramadol users in the adult Norwegian population increased more than 3-fold from 1.7% in 2004 to 4.7% in 2014. 10 Simultaneously, the prevalence of codeine use decreased from 10.6% to 9.1%. 10 Thus, the increase in tramadol outweighs the decrease in codeine use, and most of the increase in tramadol use represents increasing opioid use overall.
Because the same concerns regarding problematic opioid use and overdoses apply for tramadol as for other opioids, the increasing tramadol use is concerning and needs to be investigated further. [11] [12] [13] [14] [15] [16] The Norwegian guidelines for opioid use for CNCP have always been relatively strict, emphasizing that opioids should only be prescribed to a small minority of patients after a thorough evaluation and close monitoring. 12, 17, 18 The Norwegian Directorate of Health recommends opioid treatment with one single opioid drug/formulation and avoidance of co-medication with benzodiazepines (BZDs). 19 Based on four years of follow-up, the aim was to investigate, prospectively, the drug use pattern among tramadol users in a national cohort who received tramadol in 2012, stratified according to their prior opioid exposure.
2 | METHODS
| Study design
A prospective cohort study based on data from the complete national Norwegian Prescription Database (NorPD). The study population was stratified into four groups based on previous opioid use (2 years a priori) and followed for four years. 20 It is possible to follow patients over time anonymously, as a unique encrypted personal identity number identifies the patients.
| Data source
Our study was based on the following variables: unique personal identity number, sex, age, dispensing date, and drug information including ATC code, drug quantity measured in defined daily doses (DDD) and the reimbursement code for opioids. We recorded the reimbursement code for opioids used by terminal patients in palliative care to obtain financial reimbursement of opioid cost. The code was then used as a proxy for receiving palliative care when stratifying drugs used as a palliative treatment of malignant pain or treatment of acute or CNCP.
| Study population
The analyses are based on 154 042 individuals (≥18 years), who had at least one prescription of tramadol in 2012. We stratified patients into four study population groups according to their pre-exposure level of opioid use (2 years before their first prescription of tramadol in 2012) ( 
KEY POINTS
• The study examined the drug use pattern in a national cohort of tramadol users stratified according to previous use of opioids.
• A significant minority of opioid naïve tramadol users (5.8%) developed a recurrent opioid use with a doubled increase in mean consumption and onequarter proceeded to strong opioid use.
• Strong opioid users with chronic non-cancer pain developed a prescription pattern like the pattern of patients in palliative care with a high, consistent, and increasing mean consumption of strong opioids.
• Among recurrent opioid users, a high proportion was co- 
| Analyses strategy and statistical analyses
In the analyses, the following case definitions were applied:
• Recurrent opioid users received opioids at least once during each of the four 365 day's periods.
• Consistent recurrent users met the criteria of recurrent opioid use and received six or more prescriptions of opioids during the fourth 1-year period.
• Possible concurrent drug users met the criteria for recurrent opioid use and within the fourth 365 day's period received one or more prescriptions of BZDs or Z-hypnotics.
• Possible problematic drug users met the criteria for recurrent opioid use and received, during the fourth 365 day's period, prescriptions of ≥365 DDD opioids, ≥100 DDD BZDs, and ≥100 DDD Z-hypnotics. in four different study population groups (Table 1) . Fifth, we excluded individuals, who had died/stopped using opioids, in each follow-up year ( Figure 1 ). Sixth, among recurrent opioid users, during each year of the 4-year follow-up period, we studied opioid consumption and the possible concurrent use of BZDs or Z-hypnotics (Table 2) .
Seventh, among recurrent opioid users, at the fourth year of followup, we studied: (1) the prevalence of possible concurrent users of BZDs and Z-hypnotics (Table 3) , (B) the prevalence of consistent recurrent opioid users, and (C) the prevalence of possible problematic drug users.
All analyses were done in SPSS version 24.
| Ethical considerations
According to Norwegian legislation, the use of the anonymous population data from NorPD does not require an application to the Regional Committee for Medical Research Ethics nor informed consent.
3 | RESULTS
| Study population
In 2012, 3.9% of the adult population (≥18 years) in Norway received at least one prescription of tramadol (154 042 out of 3 932 250 
| Recurrent opioid users
The proportions of recurrent opioid users (defined by use in 2016) were, 5.8% (n = 3476) in opioid naïve tramadol users, 39.8% (n = 27 765) in former weak opioid users, 60.7% (n = 4664) in former strong opioid users, and 70.0% (n = 1251) in users in palliative care (Figure 1 ).
When the recurrent users, within each of the four groups, were followed for 4 years the opioid naïve tramadol users almost doubled their mean opioid consumption from 66 DDD to 108 DDD, and former weak opioid users increased their mean opioid consumption from 173 to 191 DDD (Table 2) . Throughout the study period, former We found a stable and high proportion of BZD users in all groups during follow-up (Table 2 ). In the first 1-year follow-up period, the proportion of possible concurrent users of BZDs was 23.8% of opioid naïve tramadol users, 34.8% of former weak opioid users, 47.8% of former strong opioid users, and 46.8% of users in palliative care.
During follow-up, both the 1-year periodic prevalence and doses of BZDs were stable in all groups, but highest among former strong opioid users and users in palliative care (Table 2 ).
| Opioids and Z-hypnotics
The proportion of possible concurrent Z-hypnotics users was even higher than the possible concurrent use of BZDs and remained stable during follow-up (Table 2) . In all groups, more than 30% had a recurrent use of Z-hypnotics, receiving at least one prescription of Z-hypnotics during each of the four 1-year periods. Doses and 1-year periodic prevalence were high and stable during follow-up with a slight increase among opioid naïve tramadol users (Table 2 ).
| Opioids, benzodiazepines, and Z-hypnotics
In the fourth year of follow-up, among recurrent users, 11.9% of opioid naïve tramadol users had a possible concurrent use of opioids, BZDs, and Z-hypnotics, compared with 18.3% of former weak opioid users, 26.6% of former strong opioid users, and 25.5% of users in palliative care (Table 3) . In patients receiving all three drugs, the opioid doses were higher than the average in each group (Table 3) .
| Consistent recurrent opioid users
In the fourth year of follow-up, among those who became recurrent opioid users: 40.3% of opioid naïve tramadol users, 58.6% of weak opioid users, 76.1% of strong opioid users, and 78.6% of users in palliative care were defined as consistent recurrent opioid users (Data not shown).
| Possible problematic drug users
The criteria of possible problematic drug use (during the fourth 365 day's period: ≥365 DDD opioids, ≥100 DDD BZDs, and ≥100 DDD Z-hypnotics) were met by 0.5% of opioid naïve tramadol users, 2.2% of former weak opioid users, and 5.5% of strong opioid users.
In the group of patients receiving reimbursement for palliative treatment, 6.8% met the same criteria.
| DISCUSSION
The main finding was that although only 5.8% of opioid naïve tramadol users became recurrent users, these patients doubled the annual opioid dose during the 4-year follow-up, one-fifth proceeded to strong opioids, more than one-third had a consistent recurrent use, one-quarter was co-medicated with BZDs, one-third was co-medicated with Z-hypnotics, and one-tenth was co-medicated with both drugs. Thus, in a significant minority (about 1/20) of patients using tramadol, their first opioid prescription may be the first step towards a long-term opioid use that in many patients is combined with using other drugs with addiction potential. In the two non-palliative care patient's groups, who had been former users of weak or strong opioids before receiving tramadol, the rates of recurrent use (39.8%, 60.7%), consistent recurrent use (58.6%, 76.1%), and possible problematic drug use (2.2%, 5.5%) were
higher. This prescription pattern indicates that these patients have developed or are at risk of developing problematic opioid use.
Another concern is that the group of former strong opioids users had a prescription pattern quite similar to the users in palliative care, even though guidelines and treatment principles for opioids in these two patient populations differ substantially. 23 Acute pain conditions tend to follow a predictable and linear trajectory and usually respond well to opioids. In contrast, opioid treatment for chronic pain with no predictable or linear trajectory often only initially provides pain relief.
In addition, many bio-psycho-social factors influence the experience, perception, and report of chronic pain, which can explain why long-term opioid treatment for chronic pain does not deliver expected outcomes including lowering pain scores. Because of chronic pain conditions' complexity, it is inappropriate to offer the simple stepladder approach which is more suitable for cancer-related pain conditions. 23, 24 New opioid users' drug use pattern has previously been investigated in studies based on the NorPD. 25, 26 One study found that 7%
of new weak opioid users had a repeated opioid use (received an opioid prescription at least once during each of 4 years) and only 0.08% developed a prescription pattern indicating problematic opioid use (>365 DDD of opioids during each of 4 years, opioid prescriptions
The possible concurrent drug use of opioids, benzodiazepines, and Z-hypnotics, at the fourth year of follow-up, in recurrent opioid users (who have used opioids in each of all four years from 2012 to 2016), stratified into four different study population groups n (%) from >3 doctors, and >100 DDDs of BZDs concurrently). 25 This result corresponds to our findings except that we found higher proportions of recurrent users (0.5%-6.8%) with a possible problematic drug use.
However, an accurate comparison between these pharmaco-epidemiological studies can be difficult due to different study designs and different criteria for problematic opioid use such as symptoms of physiological and psychological dependence, dose escalations, and prolonged treatment periods. 27 Notably, our design enables us to explore the dose progress, shift to strong opioids, and co-medication in both opioid naïve tramadol user and former opioid users.
In 2015, 17% of the Norwegian population received opioid treatment and the rate of high-risk opioid users was 2.7/1.000 in 2013. 28 
| Strengths and limitations
This study's strength is that it is based on a complete national database covering the entire Norwegian population, which minimizes the risk of selection and information bias. Furthermore, the use of NorPD enables to follow cohorts over time.
It is a limiting factor that NorPD does not provide information about drug use during hospitalization/other institutions, which can cause a minor underestimation of the actual drug use. As hospitalization increases with age, underestimation is most likely in the elderly, ETHICS STATEMENT
